Status:

COMPLETED

DS2330b Alone and With Sevelamer in Patients on Chronic Hemodialysis

Lead Sponsor:

Daiichi Sankyo

Conditions:

Hyperphosphatemia

Eligibility:

All Genders

18-80 years

Phase:

PHASE1

Brief Summary

This three-part study will be performed with participants on chronic hemodialysis. * Part A will assess plasma pharmacokinetics of DS2330a (free form of DS2330b) after a single dose of powder in bott...

Eligibility Criteria

Inclusion

  • Has a body mass index (BMI) of 18 kg/m\^2 to 40 kg/m\^2 (inclusive)
  • Is on prescribed maintenance hemodialysis (three times a week) for at least 3 months before Screening with adequacy demonstrated by a dialysis clearance within 3 months before the first dose of the investigational medicinal product
  • Has permanent vascular access \[arteriovenous (A-V) fistula or graft\]
  • Is willing to comply with protocol-specified methods for family planning
  • For Parts B and C only:
  • Has protocol-specified acceptable serum Pi levels at Screening and in serum Pi after up to 3 weeks of washout from all Pi binders
  • Has protocol-specified acceptable serum Ca\^2+ level and intact parathyroid hormone (iPTH) level at screening

Exclusion

  • Is employed by the clinic or the sponsor
  • Has family relationship with another study participant
  • Has any history, current condition, or drug use that per protocol or in the opinion of the investigator might compromise:
  • safety of the participant or their children
  • safety of study staff
  • analysis of study results
  • For Parts B and C only:
  • Is not able to take sevelamer carbonate
  • Has had partial or total parathyroidectomy within the last six months

Key Trial Info

Start Date :

August 17 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 3 2019

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT03305471

Start Date

August 17 2017

End Date

January 3 2019

Last Update

March 25 2019

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

DaVita Clinical Research

Lakewood, Colorado, United States, 80228

2

Orlando Clinical Research Center

Orlando, Florida, United States, 32809

3

DaVita Clinical Research

Minneapolis, Minnesota, United States, 55404

4

Prism Clinical Research

Saint Paul, Minnesota, United States, 55114